Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor

Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly. Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs.

Guardado en:
Detalles Bibliográficos
Autores principales: Dirk Roymans, Sarhad S Alnajjar, Michael B Battles, Panchan Sitthicharoenchai, Polina Furmanova-Hollenstein, Peter Rigaux, Joke Van den Berg, Leen Kwanten, Marcia Van Ginderen, Nick Verheyen, Luc Vranckx, Steffen Jaensch, Eric Arnoult, Richard Voorzaat, Jack M. Gallup, Alejandro Larios-Mora, Marjolein Crabbe, Dymphy Huntjens, Pierre Raboisson, Johannes P. Langedijk, Mark R. Ackermann, Jason S McLellan, Sandrine Vendeville, Anil Koul
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/a53af0caadf64c108081ce0c70f541ee
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly. Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs.

Ejemplares similares